ClinicalTrials.gg
Active, not recruitingNCT07217015BROADEN2Updated Oct 6, 2026

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of KT-621 and Placebo in Atopic Dermatitis, sponsored by Kymera Therapeutics, Inc.. Active, not recruiting at 61 sites in 8 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Kymera Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 6, 20261 site added8 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Planned enrollment
171st of 544
200 · median 96
Started
2025
with 40 others
Phase 2
202 of 639
18 open now
Primary completion
2027-06
later than 51 of 115 live
Registered
605th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 171st largest by planned enrollment of the 544 interventional ones that give a count, is one of 41 that started in 2025, is one of 202 in phase 2, reaches primary completion later than 51 of the 115 other live ones, and was the 605th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • STAT6
  • stat6 degrader
  • targeted protein degrader
  • Phase 2
  • Phase 2b
  • kt-621
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be 12 to 75 years of age, inclusive, at the time of signing the IAF (informed assent form) and/or ICF ( form).
  • Must have chronic AD that has been present for at least 3 years (for participants ≥ 18 years of age) or 1 year (for participants \< 18 years of age) before the Screening visit.
  • Must have an EASI score ≥ 16 at the Screening and Baseline visits.
  • Must have a vIGA-AD score ≥ 3 (scale of 0 to 4) at the Screening and Baseline visits.
  • Must have at least 10% BSA of AD involvement at the Screening and Baseline visits.
  • Must have a weekly average Peak Pruritus NRS value ≥ 4 at the Baseline visit.
  • Must have a history within the 6 months prior to the Baseline visit of either an inadequate response to, or inability to take, topical medications for the treatment of AD.
  • Must apply a stable dose of moisturizer at least twice daily for at least 7 consecutive days immediately prior to the Baseline visit. Participants should be willing to continue using moisturizer twice daily during the study.
  • Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.
  • Must agree to requirements in compliance with the clinical study and local requirements.

Exclusion criteria

Exclusion Criteria:

  • Must not have an unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the Investigator in the 4 weeks before the baseline visit.
  • Must not have other skin conditions, such as contact dermatitis, psoriasis, tinea corporis, or lupus erythematosus, that may interfere with study assessments.
  • Must not have a history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, ophthalmological, or connective tissue diseases or disorders.
  • Must not have any surgical or medical procedure planned during participation in the study.
  • Must not have a history of alcohol or substance abuse within the previous 2 years.
  • Must not be pregnant or breastfeeding; must not be a woman planning to become pregnant or breastfeed during the study.
  • Must not have a history of lack of response to any medication targeting interleukin (IL)-4, IL-13, and/or janus kinase (JAK)- signal transducer and activator of transcription (STAT) pathways (e.g. dupilumab, tralokinumab, upadacitinib, abrocitinib) at approved doses after at least 16 weeks of therapy.
  • Must not have results from clinical laboratory safety tests that are outside the local reference range at Screening.
  • Must not have been dosed with any drug or device in a clinical study within 8 weeks or 5 half-lives (whichever is longer) of KT-621 administration.
  • Female participants of must not have a positive or undetermined pregnancy result at the Screening and baseline visits.
  • Must not have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results.
  • Must not be taking or have taken any prespecified prohibited therapies within a specific timeframe as evaluated by the Investigator.
  • Must not have a known sensitivity to any of the components of KT-621.
  • Must not be a member of the investigational team or his/her immediate family.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Group 1: KT-621 Dose 1

    Drug: KT-621

  • Experimental
    Group 2: KT-621 Dose 2

    Drug: KT-621

  • Experimental
    Group 3: KT-621 Dose 3

    Drug: KT-621

  • Placebo comparator
    Group 4: Placebo

    Other: Placebo

Interventions

  • DrugKT-621

    Oral drug

  • OtherPlacebo

    Oral placebo matched to KT-621

06

What researchers measure

Primary outcomes

  1. Change from baseline in Eczema Area and Severity Index (EASI) score

    Time frame: From baseline through Week 16

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: From baseline through Week 16, and from Week 16 through Week 68

  2. Incidence of treatment-emergent serious adverse events (SAEs)

    Time frame: From baseline through Week 16, and from Week 16 through Week 68

  3. Percentage change from baseline in body surface area (BSA) affected by AD

    Time frame: From baseline to Week 16 and to Week 68

  4. Percentage change from baseline in the Peak Pruritus NRS score

    Time frame: From baseline to Week 16, and to Week 68

  5. Proportion of participants with at least a 4-point improvement from baseline in the Peak Pruritus Numerical Rating Scale (NRS)

    Time frame: At Week 16 and at Week 68

  6. Proportion of participants who achieve a validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score of 0 to 1 (on a 5-point scale) and a reduction from the baseline value of at least 2 points

    Time frame: At Week 16 and at Week 68

  7. Proportion of participants with EASI-50, EASI-75, and EASI-90

    Time frame: At Week 16 and at Week 68

  8. Percentage change from baseline in the EASI score

    Time frame: From baseline to Week 68

  9. Percentage change from baseline in the SCORing Atopic Dermatitis (SCORAD) score

    Time frame: From baseline to Week 16, and to Week 68

  10. Change from baseline in the Patient-Oriented Eczema Measure (POEM)

    Time frame: From baseline to Week 16, and to Week 68

  11. Change from baseline in the Dermatology Life Quality Index (DLQI)

    Time frame: From baseline to Week 16, and to Week 68

  12. Plasma concentration of KT-621 derived from plasma concentration time data

    Time frame: From baseline to Week 16, and to Week 68

07

Study locations

61 sites
  • Kymera Investigative Site
    Birmingham, Alabama 35244, United States
  • Kymera Investigative Site
    North Little Rock, Arkansas 72117, United States
  • Kymera Investigative Site
    Los Angeles, California 90025, United States
  • Kymera Investigative Site
    Los Angeles, California 90045, United States
  • Kymera Investigative Site
    Delray Beach, Florida 33484, United States
  • Kymera Investigative Site
    Jacksonville, Florida 32256, United States
  • Kymera Investigative Site
    Miami, Florida 33137, United States
  • Kymera Investigative Site
    Miami, Florida 33162, United States
  • Kymera Investigative Site
    Miramar, Florida 33027, United States
  • Kymera Investigative Site
    Normal, Illinois 61761, United States
  • Kymera Investigative Site
    Ann Arbor, Michigan 48103, United States
  • Kymera Investigative Site
    Detroit, Michigan 48202, United States
  • Kymera Investigative Site
    The Bronx, New York 10455, United States
  • Kymera Investigative Site
    Fargo, North Dakota 58103, United States
  • Kymera Investigative Site
    Portland, Oregon 97201, United States
  • Kymera Investigative Site
    Portland, Oregon 97239, United States
  • Kymera Investigative Site
    Philadelphia, Pennsylvania 19103, United States
  • Kymera Investigative Site
    San Antonio, Texas 78213, United States
  • Kymera Investigative Site
    San Antonio, Texas 78218, United States
  • Kymera Investigative Site
    Darlinghurst, New South Wales, Australia
  • Kymera Investigative Site
    Kogarah, New South Wales, Australia
  • Kymera Investigative Site
    Brisbane, Queensland, Australia
  • Kymera Investigative Site
    Woolloongabba, Queensland, Australia
  • Kymera Investigative Site
    Melbourne, Victoria, Australia
  • Kymera Investigative Site
    Calgary, Alberta, Canada
  • Kymera Investigative Site
    Edmonton, Alberta, Canada
  • Kymera Investigative Site
    Kelowna, British Columbia, Canada
  • Kymera Investigative Site
    Surrey, British Columbia, Canada
  • Kymera Investigative Site
    Markham, Ontario, Canada
  • Kymera Investigative Site
    Ottawa, Ontario, Canada
  • Kymera Investigative Site
    Richmond Hill, Ontario, Canada
  • Kymera Investigative Site
    Toronto, Ontario, Canada
  • Kymera Investigative Site
    Québec, Quebec, Canada
  • Kymera Investigative Site
    Pardubice, Czechia
  • Kymera Investigative Site
    Prague, Czechia
  • Kymera Investigative Site
    München, Bavaria, Germany
  • Kymera Investigative Site
    Bad Bentheim, Germany
  • Kymera Investigative Site
    Frankfurt, Germany
  • Kymera Investigative Site
    Mainz, Germany
  • Kymera Investigative Site
    Münster, Germany
  • Kymera Investigative Site
    Ichikawa, Chiba, Japan
  • Kymera Investigative Site
    Kagoshima, Japan
  • Kymera Investigative Site
    Kanagawa, Japan
  • Kymera Investigative Site
    Nagoya, Japan
  • Kymera Investigative Site
    Osaka, Japan
  • Kymera Investigative Site
    Sakai, Japan
  • Kymera Investigative Site
    Sapporo, Japan
  • Kymera Investigative Site
    Chorzów, Poland
  • Kymera Investigative Site
    Gdansk, Poland
  • Kymera Investigative Site
    Gdynia, Poland
  • Kymera Investigative Site
    Krakow, Poland
  • Kymera Investigative Site
    Lublin, Poland
  • Kymera Investigative Site
    Rzeszów, Poland
  • Kymera Investigative Site
    Szczecin, Poland
  • Kymera Investigative Site
    Warsaw, Poland
  • Kymera Investigative Site
    Wroclaw, Poland
  • Kymera Investigative Site
    Ansan-si, South Korea
  • Kymera Investigative Site
    Cheonan, South Korea
  • Kymera Investigative Site
    Gyeonggi-do, South Korea
  • Kymera Investigative Site
    Incheon, South Korea
  • Kymera Investigative Site
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2027, 19 months after the start.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 19 months is above that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2025
First posted
Oct 15, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 8 sites removed
Show site
  • Kymera Investigative Site · Miami, United States
Show 8 removed
  • Kymera Investigative Site · Freemont, United States
  • Kymera Investigative Site · Santa Monica, United States
  • Kymera Investigative Site · Indianapolis, United States
  • Kymera Investigative Site · Windsor, Canada
  • Kymera Investigative Site · Augsburg, Germany
  • Kymera Investigative Site · Berlin, Germany
  • Kymera Investigative Site · Dresden, Germany
  • Kymera Investigative Site · Friedrichshafen, Germany
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    1 site added, 8 sites removed
    Show site
    • Kymera Investigative Site · Miami, United States
    Show 8 removed
    • Kymera Investigative Site · Freemont, United States
    • Kymera Investigative Site · Santa Monica, United States
    • Kymera Investigative Site · Indianapolis, United States
    • Kymera Investigative Site · Windsor, Canada
    • Kymera Investigative Site · Augsburg, Germany
    • Kymera Investigative Site · Berlin, Germany
    • Kymera Investigative Site · Dresden, Germany
    • Kymera Investigative Site · Friedrichshafen, Germany
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07217015
Lead sponsor
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Oct 15, 2025
Start date
Nov 24, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KT-621

Start the discussion